Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Macme Dec. 7 at 4:00 AM

$CAPR Outcomes by Population Overall Trial Results (all patients) Upper Limb Function (PUL v2.0): Decline slowed by 54% vs placebo. Cardiac Function (LVEF): Decline slowed by 91% vs placebo. Safety: Favorable, consistent with earlier HOPE‑2 data. Ambulant Patients Functional Benefit: Ambulation endpoints (like 6‑minute walk) were not the primary focus, but ambulant boys still showed preservation of upper limb strength and cardiac function. Implication: Even while walking ability was relatively preserved, Deramiocel helped maintain arm function and protect the heart — both critical as disease progresses. Non‑Ambulant Patients Functional Benefit: Clear slowing of upper limb decline, which is especially important once ambulation is lost. Cardiac Benefit: Strong effect across both groups, but particularly meaningful for non‑ambulant patients who face higher cardiac risk.

1 · Reply

UWHusky Dec. 7 at 3:49 AM

$CAPR The outstanding warrants & exercisable options are now all in the money so I'd expect most of them to be exercised this month. There are 4.935M warrants & 8.224M in vested options as of the Q3 10-Q.

0 · Reply

ducruacuteo11 Dec. 7 at 3:34 AM

$CAPR so do we keep buying here at $25 or above or wait and buy on every dip? What would be the expectation from here? $300 three years from now?

1 · Reply

hegdaom Dec. 7 at 3:34 AM

$CAPR

0 · Reply

Joby099 Dec. 7 at 2:57 AM

$CAPR

0 · Reply

BioCapitalFund Dec. 7 at 2:50 AM

$CAPR Capricor's latest great news is on the both "Parent Project Muscular Dystrophy" and "Coalition Duchenne" websites' front pages. Now, these organizations will push FDA even harder to approve Deramiocel urgently. https://www.facebook.com/parentprojectmd/ https://www.facebook.com/CoalitionDuchenne/ Our first major target PPS of $200 is not that far away as stated on my previous post below. (6:50pm, Saturday, California) Bullish

2 · Reply

polloboy Dec. 7 at 2:01 AM

$CAPR guess there’s an idiot on every board!

0 · Reply

hegdaom Dec. 7 at 1:55 AM

$CAPR

0 · Reply

MoneyGroupLLC Dec. 7 at 1:52 AM

Enter: $CAPR Calls Strike Price: $30 Expiry Date: JAN 16 2026 Buy in Price: $2.64 - $3.00 Sell Price: $3.80 Profit : +44% (Turn every $1 into $1.44) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

quickaspeter Dec. 7 at 1:41 AM

$ALT What happened with $CAPR …over 500% spike is coming…after all this time I now feel it that in my vains💥🚀💰💰💰

0 · Reply

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 2 days ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 3 days ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 3 days ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 3 days ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 12 days ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 25 days ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 4 weeks ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 5 weeks ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 2 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 2 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 2 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 2 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 2 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 3 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 4 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 4 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 4 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 5 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 5 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 5 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 5 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Jul 11, 2025, 4:53 PM EDT - 5 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Macme Dec. 7 at 4:00 AM

1 · Reply

UWHusky Dec. 7 at 3:49 AM

0 · Reply

ducruacuteo11 Dec. 7 at 3:34 AM

$CAPR so do we keep buying here at $25 or above or wait and buy on every dip? What would be the expectation from here? $300 three years from now?

1 · Reply

hegdaom Dec. 7 at 3:34 AM

$CAPR

0 · Reply

Joby099 Dec. 7 at 2:57 AM

$CAPR

0 · Reply

BioCapitalFund Dec. 7 at 2:50 AM

2 · Reply

polloboy Dec. 7 at 2:01 AM

$CAPR guess there’s an idiot on every board!

0 · Reply

hegdaom Dec. 7 at 1:55 AM

$CAPR

0 · Reply

MoneyGroupLLC Dec. 7 at 1:52 AM

0 · Reply

quickaspeter Dec. 7 at 1:41 AM

$ALT What happened with $CAPR …over 500% spike is coming…after all this time I now feel it that in my vains💥🚀💰💰💰

0 · Reply

Juba2022 Dec. 7 at 1:21 AM

$CAPR Pumpy dumpy.,,,No Revenues......offering to continue operation.....7 months to FDA approval/decline....for now it is too high....ripe of more offering while excitement @ all time high....will be back below 10 in no time....and yeah if you are still excited...you can always buy more under 10.xx.....newbie! don t fall for the hype....6 million more shares will be dumped starting monday and another 900 shares as well....Don t be exit liquidity....fake bulls will attack this post....

8 · Reply

moneybagchilling Dec. 7 at 12:40 AM

$CAPR

0 · Reply

jacksparo Dec. 7 at 12:32 AM

$CAPR My story here didn’t start just recently. I wish my old fella here remember when I started here it was almost two years ago or so. My last buying block were below 5 . CAPR was in my emails multiple times. And by the way when I share a trade in my emails or telegram live group I share entry exit and a full plan. My strategy and method is not similar to others that they may keep say oh we called this or we said that before you did. I am not and I don’t think it is smart to make it look as a competition. We are retail traders and we all want to win some in this market. Also no one can come and say oh Jack front loaded … You know why because I share my trade ideas based on plans not randomly and sometimes I don’t even trade the stock because my orders don’t get filled but in the meantime a lot of my team do very well and that’s what matters for me! Enjoy your weekend!

4 · Reply

Markland55 Dec. 7 at 12:17 AM

$CAPR stick to the game plan is all I have to say I will be enjoying dinner with my wife and friends tonight but I thought this would be nice to post for inspiration 5+ years ago and x more amount of shares later (use your imaginations and check post history ) Great week and the party has just begun ! Cheers to the next 5 years

7 · Reply

Compassion Dec. 7 at 12:14 AM

$CAPR $PATH $ZIM $IRBT $SERV

0 · Reply

Steadyrockin Dec. 6 at 11:56 PM

$CAPR https://stockcharts.com/sc3/ui/?s=CAPR&a=975778602 That's a big ass candle on the weekly chart

0 · Reply

Dragonfly41 Dec. 6 at 11:33 PM

$CAPR The bulls won the battle Enjoy the prize from now on Pps will keep going higher just like ABVX as I predicted Believe what you have invested for long term Only good news from now on I predict Pps reaching over $100 before Feb next year

1 · Reply

GreenEnergy2022 Dec. 6 at 11:21 PM

$ALT we all know $CAPR went to the moon recently, lets see if ALT will do the same on 48w data

3 · Reply

Smartvestor78 Dec. 6 at 10:17 PM

$CAPR

1 · Reply

Groggok Dec. 6 at 10:12 PM

$CAPR While the FDA gave Stealth a PDUFA date for Feb. 15, 2026, the agency said in August that it planned on providing a decision by Sept. 26. The sense of urgency was likely fueled by a wide-ranging public outcry surrounding the agency’s several delays and refusal to approve the rare disease candidate. https://www.fiercepharma.com/pharma/fda-greenlights-stealth-bios-injection-1st-treatment-barth-syndrome

0 · Reply

Groggok Dec. 6 at 9:51 PM

$CAPR HOPE-3 results beat expectations this week — and remember, FDA has shown it can move fast. Stealth Bio went from filing to approval in ~1 month vs. the usual 6-month Class 2 review. With a clear unmet need in DMD, CAPR could be positioned for a similarly rapid turnaround. #biotech #CAPR

1 · Reply

CAPPdaddy Dec. 6 at 9:49 PM

$CAPR Part 3 It has been an honor reading the posts from all the GOATs on this board over the years. Many GOATs to list them all. To name a few, shout out and THANK YOU to @Keith1004 @Markland55 @Asher77 @LineBacker04 @gusm17 @jacksparo @Cote0924 @cninc @dnfrs @rogertrades @Macme @quito_yume @patatechaude @WBinthehouse

2 · Reply

Market Cap	1.23B
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-181.72%
Debt to Equity Ratio	0.00

Volume	7,040,700
Avg Vol	3,057,204
Day's Range	N/A - N/A
Shares Out	45.72M
Stochastic %K	63%
Beta	0.61
Analysts	Strong Sell
Price Target	$41.00